Aliases & Classifications for Ocular Hypotension

MalaCards integrated aliases for Ocular Hypotension:

Name: Ocular Hypotension 12 42 14 69
Hypotony of Eye 12

Classifications:



External Ids:

Disease Ontology 12 DOID:790
ICD10 33 H44.4 H44.40
ICD9CM 35 360.3 360.30
MeSH 42 D015814
UMLS 69 C0028841

Summaries for Ocular Hypotension

MalaCards based summary : Ocular Hypotension, also known as hypotony of eye, is related to primary eye hypotony and ocular hypertension, and has symptoms including eye manifestations An important gene associated with Ocular Hypotension is HTR2B (5-Hydroxytryptamine Receptor 2B), and among its related pathways/superpathways are Signaling by GPCR and DAG and IP3 signaling. The drugs Dorzolamide and Timolol have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and lung.

Related Diseases for Ocular Hypotension

Diseases related to Ocular Hypotension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
id Related Disease Score Top Affiliating Genes
1 primary eye hypotony 11.0
2 ocular hypertension 9.9
3 mental retardation cataracts calcified pinnae myopathy 9.9 ADRB1 ADRB2
4 open-angle glaucoma 9.9
5 aortopulmonary window 9.9 ADRB1 ADRB2
6 craniosynostosis 9.9 ADRB1 ADRB2
7 cataract 9.7
8 diabetic macular edema 9.7
9 polymicrogyria, bilateral frontoparietal 9.6 ADRB1 ADRB2
10 leprosy 9.6
11 uveitis 9.6
12 anterior uveitis 9.6
13 labyrinthitis 9.4 PDE4B PDE4D
14 mixed astrocytoma-ependymoma 7.6 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D

Comorbidity relations with Ocular Hypotension via Phenotypic Disease Network (PDN):


Glaucoma 1, Open Angle, F Pigment Dispersion Syndrome

Graphical network of the top 20 diseases related to Ocular Hypotension:



Diseases related to Ocular Hypotension

Symptoms & Phenotypes for Ocular Hypotension

UMLS symptoms related to Ocular Hypotension:


eye manifestations

Drugs & Therapeutics for Ocular Hypotension

Drugs for Ocular Hypotension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
2
Timolol Approved Phase 4 26839-75-8 33624 5478
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
4
Carteolol Approved Phase 4 51781-06-7 2583
5
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
6
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
7
Midodrine Approved Phase 4,Phase 2 133163-28-7, 42794-76-3 4195
8
Clonidine Approved Phase 4,Phase 1 4205-90-7 2803
9
Ergonovine Approved Phase 4 60-79-7 443884
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
11
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
12
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
13
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
14
Ephedrine Approved Phase 4,Phase 2,Phase 1 299-42-3 9294
15
Morphine Approved, Investigational Phase 4 57-27-2 5288826
16
Pseudoephedrine Approved Phase 4,Phase 2,Phase 1 90-82-4 7028
17
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
18
Oxymetazoline Approved Phase 4,Phase 1 1491-59-4 4636
19
Phenylephrine Approved Phase 4,Phase 1 59-42-7 6041
20
Ethanol Approved Phase 4 64-17-5 702
21
Menthol Approved Phase 4 2216-51-5 16666
22
Diphenhydramine Approved Phase 4 58-73-1, 147-24-0 3100
23
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
24
Promethazine Approved Phase 4 60-87-7 4927
25 tannic acid Approved, Nutraceutical Phase 4
26 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 1
29 Anti-Arrhythmia Agents Phase 4,Phase 1,Phase 2
30 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Carbonic Anhydrase Inhibitors Phase 4
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
35 Antiemetics Phase 4,Phase 3,Phase 1
36 Anti-Inflammatory Agents Phase 4,Phase 3
37 Antineoplastic Agents, Hormonal Phase 4,Phase 3
38 BB 1101 Phase 4,Phase 3
39 Dexamethasone acetate Phase 4,Phase 3 1177-87-3
40 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
41 glucocorticoids Phase 4,Phase 3
42 HIV Protease Inhibitors Phase 4,Phase 3
43 Hormone Antagonists Phase 4,Phase 3
44 Hormones Phase 4,Phase 3
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
46
protease inhibitors Phase 4,Phase 3
47 Ophthalmic Solutions Phase 4,Phase 1,Phase 2
48 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2
49 Sympatholytics Phase 4,Phase 1
50 Anticonvulsants Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 90)

id Name Status NCT ID Phase Drugs
1 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
2 Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation Unknown status NCT00326729 Phase 4
3 A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients Completed NCT00972426 Phase 4 carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
4 COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy Completed NCT01228149 Phase 4 Trabeculectomy with preoperative Diamox/DexaEDO treatment;Trabeculectomy with preoperative Cosopt S treatment
5 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
6 Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise Completed NCT00312416 Phase 4 Clonidin;Brimonidine
7 Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach Completed NCT02135146 Phase 4 Plasmalyte 3ml/kg/hr group;Plasmalyte 6ml/kg/hr group
8 Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study Completed NCT00707928 Phase 4 nitroglycerine
9 Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction Recruiting NCT02590822 Phase 4
10 CSE for Labour Analgesia: A Comparison of Two Intrathecal Regimens Not yet recruiting NCT03117595 Phase 4 Bupivacaine-fentanyl;Bupivacaine-fentanyl morphine
11 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
12 Ephedrine vs Phenylephrine - ECG Changes Terminated NCT01243970 Phase 4 Phenylephrine;Ephedrine
13 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
14 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
15 Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy Completed NCT00315796 Phase 3
16 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
17 Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants Completed NCT00358748 Phase 3 Hydrocortisone
18 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3 Droxidopa
19 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Completed NCT01522235 Phase 2, Phase 3 Double blinded IVIg
20 Co-administration of Propofol and Remifentanil for Lumbar Puncture in Children Completed NCT00405522 Phase 3 Propofol + Remifentanil;Propofol + Remifentanil
21 Efficacy and Safety of Primovist in Chinese Patients Completed NCT00526188 Phase 3 Gadoxetic Acid Disodium (Primovist, BAY86-4873)
22 Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial Completed NCT01326676 Phase 3 Polypill: Red Heart Pill;Usual medication
23 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy Withdrawn NCT01560091 Phase 3 silodosin;Tamsulosin
24 Aqueous Mushroom Extract and Intraocular Pressure Unknown status NCT01017068 Phase 1, Phase 2 OME;OME;OME;OME;OME;OME
25 A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Completed NCT01123785 Phase 1, Phase 2 INO-8875;Placebo
26 Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI Completed NCT02307526 Phase 2 Pyridostigmine Bromide
27 A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride Completed NCT00426842 Phase 2 Midodrine Hydrochloride
28 Transcranial Electrical Stimulation for Management of Orthostatic Instability in Acute Cervical Spinal Cord Injury Completed NCT01874782 Phase 2
29 A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension Completed NCT00522925 Phase 2 PS433540;placebo;PS433540
30 Acute Effects of Inhaled Treprostinil in Fontan Patients Recruiting NCT02769624 Phase 2 Treprostinil;Placebo
31 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Recruiting NCT02415608 Phase 2 Ibrutinib
32 a Prospective Cohort Study for Propranolol Treatment in Retinopathy of Prematurity Not yet recruiting NCT03038295 Phase 2 Propranolol;placebo
33 Intraocular Pressure During Prone Spinal Surgery Terminated NCT00176722 Phase 2
34 A Study of Norepinephrine in Patients With Congenital Insensitivity to Pain and Anhidrosis Withdrawn NCT02624310 Phase 2 Droxidopa (L-DOPS);Placebo
35 Effects of Hesperidin on Insulin Sensitivity Withdrawn NCT01773486 Phase 2 Hesperidin;Placebo
36 Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa Completed NCT01149629 Phase 1 Droxidopa;Droxidopa;Droxidopa
37 Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin Completed NCT01100021 Phase 1 Tamsulosin and avanafil;Doxazosin and avanafil
38 Effects of Endotoxin in Normal Human Volunteers Completed NCT00001303 Phase 1 Reference Endotoxin;Inhaled Nitric Oxide
39 The Pathophysiology of Orthostatic Hypotension Active, not recruiting NCT00748059 Phase 1 phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine;clonidine,yohimbine,metoclopramide,alpha-methyldopa
40 Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome Enrolling by invitation NCT03019653 Phase 1 ANX-042;Placebo
41 Long-Term IOP Fluctuation and VF Progression After Triple Procedure Completed NCT00428740
42 PIO Laser Sclerectomy IOP SLT Sclerectomy Completed NCT01798732
43 Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab Completed NCT00892398 ranibizumab
44 Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes Completed NCT00773136 Bimatoprost Suspension
45 Comparison of Phacotrabeculectomy and Trabeculectomy in the Treatment of Primary Angle-closure Glaucoma (PACG) Completed NCT01298635
46 Selective Laser Trabeculoplasty After Failed Phacoemulsification With Eximer Laser Trabeculectomy Completed NCT02434250
47 Primary Angle Closure Glaucoma and Aqueous Dynamics Completed NCT00719290
48 Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep Anesthesia Completed NCT02764398
49 Predicting Hypotension Related to Spinal Anesthesia Completed NCT01279889
50 Can Augmentation Index (AIx) be Used to Predict Hypotension After Spinal Anesthesia? Completed NCT00884026

Search NIH Clinical Center for Ocular Hypotension

Cochrane evidence based reviews: ocular hypotension

Genetic Tests for Ocular Hypotension

Anatomical Context for Ocular Hypotension

MalaCards organs/tissues related to Ocular Hypotension:

39
Eye, Liver, Lung, Endothelial, Kidney, Placenta, Heart

Publications for Ocular Hypotension

Articles related to Ocular Hypotension:

(show top 50) (show all 67)
id Title Authors Year
1
Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost. ( 28538979 )
2017
2
Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive Treatment. ( 25719991 )
2015
3
ADRB1 and ADBR2 gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects. ( 24749907 )
2014
4
The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study. ( 25319729 )
2014
5
Impact of ocular hypotensive lipids on clinically significant diabetic macular edema. ( 22267460 )
2012
6
Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. ( 21794845 )
2011
7
Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. ( 20426763 )
2010
8
Morphine-induced ocular hypotension is modulated by nitric oxide and carbon monoxide: role of mu3 receptors. ( 20148660 )
2010
9
Ocular hypotension and hypotony in multibacillary leprosy patients; at diagnosis, during and after completion of multidrug therapy. ( 21434594 )
2010
10
Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study. ( 19210139 )
2009
11
Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. ( 19234340 )
2009
12
Prolonged ocular hypotension: would ciliary tissue transplantation help. ( 19098698 )
2009
13
Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. ( 18992242 )
2009
14
Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? ( 18460537 )
2008
15
Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. ( 17565920 )
2007
16
Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. ( 17238805 )
2006
17
Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. ( 16968567 )
2006
18
Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. ( 17056362 )
2006
19
Fadolmidine-induced ocular hypotension in normotensive rabbits. ( 15720782 )
2005
20
PD128,907 induces ocular hypotension in rabbits: involvement of D2/D3 dopamine receptors and brain natriuretic peptide. ( 15006155 )
2004
21
Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. ( 15216404 )
2004
22
Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. ( 15037111 )
2004
23
New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. ( 14646172 )
2003
24
Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. ( 12676887 )
2003
25
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. ( 14733708 )
2003
26
Cystoid macular edema in the era of ocular hypotensive lipids. ( 11915838 )
2002
27
Ocular hypotension induced by electroacupuncture. ( 12222760 )
2002
28
Cystoid macular edema associated with ocular hypotensive lipids. ( 11860980 )
2002
29
Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. ( 10614682 )
2000
30
2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit. ( 10882008 )
2000
31
Mechanism of exercise-induced ocular hypotension. ( 10102302 )
1999
32
8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action. ( 10433858 )
1999
33
Lisuride acts at multiple sites to induce ocular hypotension and mydriasis. ( 9742290 )
1998
34
Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. ( 9851310 )
1998
35
Ocular hypotension induced by intravitreally injected C-type natriuretic peptide. ( 9533834 )
1998
36
Ocular hypotensive effect of topical ketanserin in timolol users. ( 9085107 )
1997
37
Potential mechanisms of moxonidine-induced ocular hypotension: role of norepinephrine. ( 9436152 )
1997
38
Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. ( 8921215 )
1996
39
Molecular characterization and ocular hypotensive properties of the prostanoid EP2 receptor. ( 8590276 )
1995
40
Centrally mediated ocular hypotension: potential role of imidazoline receptors. ( 7677360 )
1995
41
Evaluation of IBMX-enhanced ocular hypotension after adrenergic agonists in the rabbit eye. ( 7542619 )
1995
42
Correlates of acute exercise-induced ocular hypotension. ( 7928182 )
1994
43
Ocular hypotension during short- and long-term hypocapnia. ( 19920601 )
1994
44
Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. ( 7925603 )
1994
45
Long-term visual outcome of ocular hypotension after thermosclerostomy. ( 8488912 )
1993
46
Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. ( 1349879 )
1992
47
PhXA34-induced ocular hypotension. ( 1463535 )
1992
48
Isobutylmethylxanthine enhances adrenergic-induced ocular hypotension in rabbits and beagles. ( 1712310 )
1991
49
Soluble forms of isobutylmethylxanthine enhance the ocular hypotension induced by catecholamines. ( 1722476 )
1991
50
Reattachment of the detached ciliary body with suturing for treatment of contusional ocular hypotension. ( 1896179 )
1991

Variations for Ocular Hypotension

Expression for Ocular Hypotension

Search GEO for disease gene expression data for Ocular Hypotension.

Pathways for Ocular Hypotension

Pathways related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
2
Show member pathways
12.47 ADRB1 ADRB2 PDE4B PDE4C PDE4D
3
Show member pathways
12.2 PDE4B PDE4C PDE4D
4 12.18 ADRB1 ADRB2 PDE4B
5
Show member pathways
12.12 ADRB2 PDE4B PDE4C PDE4D
6
Show member pathways
12.05 ADRB1 ADRB2 PDE4B PDE4D
7
Show member pathways
11.9 ADRB1 ADRB2 HTR2B
8 11.71 ADRB1 ADRB2 PDE4B
9
Show member pathways
11.66 ADRB1 ADRB2 PDE4B PDE4C PDE4D
10
Show member pathways
11.64 ADRB1 ADRB2 HTR2B
11
Show member pathways
11.5 PDE4B PDE4C PDE4D
12 11.37 ADRB1 ADRB2
13 11.28 ADRB1 ADRB2
14 11.26 ADRB1 ADRB2
15 11.19 ADRB1 ADRB2 PDE4B PDE4C PDE4D
16 10.84 ADRB1 ADRB2

GO Terms for Ocular Hypotension

Cellular components related to Ocular Hypotension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 voltage-gated calcium channel complex GO:0005891 8.62 PDE4B PDE4D

Biological processes related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.8 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
2 neutrophil chemotaxis GO:0030593 9.58 PDE4B PDE4D
3 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.58 ADRB1 ADRB2
4 positive regulation of interferon-gamma production GO:0032729 9.57 PDE4B PDE4D
5 response to cold GO:0009409 9.56 ADRB1 ADRB2
6 activation of adenylate cyclase activity GO:0007190 9.55 ADRB1 ADRB2
7 brown fat cell differentiation GO:0050873 9.54 ADRB1 ADRB2
8 smooth muscle contraction GO:0006939 9.52 HTR2B PDE4D
9 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.51 ADRB1 ADRB2
10 positive regulation of interleukin-2 production GO:0032743 9.49 PDE4B PDE4D
11 cellular response to epinephrine stimulus GO:0071872 9.48 PDE4B PDE4D
12 negative regulation of multicellular organism growth GO:0040015 9.46 ADRB1 ADRB2
13 regulation of cardiac muscle cell contraction GO:0086004 9.43 PDE4B PDE4D
14 diet induced thermogenesis GO:0002024 9.4 ADRB1 ADRB2
15 adrenergic receptor signaling pathway GO:0071875 9.37 ADRB2 PDE4D
16 vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure GO:0002025 9.26 ADRB1 ADRB2
17 heat generation GO:0031649 9.16 ADRB1 ADRB2
18 negative regulation of relaxation of cardiac muscle GO:1901898 8.96 PDE4B PDE4D
19 cAMP catabolic process GO:0006198 8.8 PDE4B PDE4C PDE4D

Molecular functions related to Ocular Hypotension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.61 ADRB1 ADRB2 HTR2B
2 ion channel binding GO:0044325 9.48 PDE4B PDE4D
3 drug binding GO:0008144 9.46 HTR2B PDE4D
4 cAMP binding GO:0030552 9.4 PDE4B PDE4D
5 3,5-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.37 PDE4B PDE4D
6 adrenergic receptor activity GO:0004935 9.32 ADRB1 ADRB2
7 epinephrine binding GO:0051379 9.26 ADRB1 ADRB2
8 norepinephrine binding GO:0051380 9.16 ADRB1 ADRB2
9 phosphoric diester hydrolase activity GO:0008081 9.13 PDE4B PDE4C PDE4D
10 3,5-cyclic-AMP phosphodiesterase activity GO:0004115 8.8 PDE4B PDE4C PDE4D

Sources for Ocular Hypotension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....